PetVivo Holdings Inc (PETV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, PetVivo Holdings Inc (PETV) has a cash flow conversion efficiency ratio of -0.438x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.63 Million) by net assets ($3.73 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
PetVivo Holdings Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how PetVivo Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read PetVivo Holdings Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
PetVivo Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PetVivo Holdings Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dcon Products Public Company Limited
BK:DCON
|
0.001x |
|
DK&D Co.Ltd
KQ:263020
|
0.078x |
|
Online Brands Nordic AB
ST:OBAB
|
0.010x |
|
Sprintex Ltd
AU:SIX
|
-0.039x |
|
Pacgold Ltd
AU:PGO
|
-0.030x |
|
Bangkok Dec-Con Public Company Limited
BK:BKD
|
-0.006x |
|
Thai Agro Energy Public Company Limited
BK:TAE
|
0.009x |
|
Modular Medical Inc
NASDAQ:MODD
|
-0.617x |
Annual Cash Flow Conversion Efficiency for PetVivo Holdings Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of PetVivo Holdings Inc from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see PetVivo Holdings Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $4.22 Million | $-5.32 Million | -1.261x | +88.34% |
| 2024-03-31 | $685.95K | $-7.42 Million | -10.816x | -15.42% |
| 2023-03-31 | $725.02K | $-6.79 Million | -9.371x | -1243.82% |
| 2022-03-31 | $5.99 Million | $-4.17 Million | -0.697x | -159.73% |
| 2021-03-31 | $-896.98K | $-1.05 Million | 1.168x | +143.63% |
| 2020-03-31 | $-1.04 Million | $-496.59K | 0.479x | -45.02% |
| 2019-03-31 | $-844.82K | $-736.45K | 0.872x | +120.57% |
| 2018-03-31 | $136.65K | $-579.15K | -4.238x | -2329.30% |
| 2017-03-31 | $819.75K | $-143.02K | -0.174x | -284.41% |
| 2016-03-31 | $15.21 Million | $-690.33K | -0.045x | +98.16% |
| 2015-03-31 | $161.25K | $-398.48K | -2.471x | -440.34% |
| 2014-03-31 | $-301.81K | $-219.13K | 0.726x | +90.00% |
| 2013-03-31 | $-184.51K | $-70.51K | 0.382x | +37.56% |
| 2012-03-31 | $-177.62K | $-49.34K | 0.278x | -87.92% |
| 2011-03-31 | $-74.99K | $-172.42K | 2.299x | -- |
About PetVivo Holdings Inc
PetVivo Holdings, Inc., a biomedical device company, manufactures, commercializes, and licenses medical devices and therapeutics for animals in the United States. The company's lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. It also provides therapeutic devices for … Read more